Literature DB >> 7457487

Diabetic neuropathy and plasma glucose control.

D Porte, R J Graf, J B Halter, M A Pfeifer, E Halar.   

Abstract

Diabetic neuropathy is defined, and theories of its pathogenesis are reviewed. Recent studies designed to investigate the influence of plasma glucose on nerve function in noninsulin-dependent diabetic patients are summarized. Motor nerve conduction velocities in the median and peroneal nerves were measured using a double-stimulus technique, and sensory conduction velocity was measured by conventional methods before and after therapy with oral agents or insulin. The degree of hyperglycemia was assessed by measurement of fasting plasma glucose and glycosylated hemoglobin concentrations. The degree of slowing in motor nerve conduction velocity in untreated patients was found to correlate with the fasting plasma glucose and glycosylated hemoglobin concentrations, but sensory nerve function, although abnormal, did not show such correlation. Reduction of hyperglycemia was associated with improvement in motor nerve conduction velocity in the peroneal and median motor nerves of these patients, but sensory nerve conduction velocity showed no such improvement. Improvement in median motor nerve conduction velocity was directly related to the degree of reduction in fasting plasma glucose concentration. These findings suggest that metabolic factors related to hyperglycemia are important in the impaired motor nerve function seen in noninsulin-dependent patients with maturity-onset diabetes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7457487     DOI: 10.1016/0002-9343(81)90426-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  14 in total

1.  Controlling blood sugars.

Authors:  A Mehta; I Matwijiw
Journal:  Can Fam Physician       Date:  1985-07       Impact factor: 3.275

2.  Effects of one year of near-normoglycemia on peripheral nerve function in type 1 (insulin-dependent) diabetic patients.

Authors:  D Ziegler; K Wiefels; K Dannehl; F A Gries
Journal:  Klin Wochenschr       Date:  1988-05-02

3.  The natural course of peripheral and autonomic neural function during the first two years after diagnosis of type 1 diabetes.

Authors:  D Ziegler; I Cicmir; P Mayer; K Wiefels; F A Gries
Journal:  Klin Wochenschr       Date:  1988-11-01

4.  The correlation between sensory nerve conduction velocities and three metabolic indices in rats treated with streptozotocin.

Authors:  P O Julu
Journal:  Diabetologia       Date:  1988-04       Impact factor: 10.122

5.  Genetic and metabolic studies in diabetic neuropathy.

Authors:  A J Boulton; R C Worth; J Drury; C A Hardisty; E Wolf; A G Cudworth; J D Ward
Journal:  Diabetologia       Date:  1984-01       Impact factor: 10.122

6.  Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.

Authors:  I G Lewin; I A O'Brien; M H Morgan; R J Corrall
Journal:  Diabetologia       Date:  1984-06       Impact factor: 10.122

7.  Influence of continuous subcutaneous insulin infusion (CSII) treatment on diabetic somatic and autonomic neuropathy.

Authors:  D Fedele; P Negrin; C Cardone; F Bellavere; M Ferri; G Briani; R Nosadini; G Crepaldi
Journal:  J Endocrinol Invest       Date:  1984-12       Impact factor: 4.256

8.  The limited clinical value of home urine testing by diabetic patients.

Authors:  J D Goodson; D E Singer; K Hurxthal; D M Nathan
Journal:  J Gen Intern Med       Date:  1986 Jul-Aug       Impact factor: 5.128

9.  The natural history of somatosensory and autonomic nerve dysfunction in relation to glycaemic control during the first 5 years after diagnosis of type 1 (insulin-dependent) diabetes mellitus.

Authors:  D Ziegler; P Mayer; H Mühlen; F A Gries
Journal:  Diabetologia       Date:  1991-11       Impact factor: 10.122

10.  Evaluation of thermal, pain, and vibration sensation thresholds in newly diagnosed type 1 diabetic patients.

Authors:  D Ziegler; P Mayer; F A Gries
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.